Hepatocellular Carcinoma-targeting Adenovirus Vector Construction Service
Optimizing targeting strategies for vectors in order to enhance anti-tumor activity and secure patient safety is important for cancer gene therapy. At Creative Biolabs, with combined expertise and advanced technologies, we are able to help develop genetically engineered regulated adenovirus that can selectively illuminate and kill cancer cells. Here, we introduce our hepatocellular carcinoma-targeting adenovirus vector construction services to our global clients.
Introduction of Hepatocellular Carcinoma
Overview of Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the fifth most common cancer, causing one-third of cancer-related deaths worldwide. It mostly develops in the cirrhotic liver, which results from different factors, including chronic viral hepatitis, alcohol abuse, inherited metabolic maladies, etc. HCCs are often diagnosed at an advanced stage and therefore, patients have a poor prognosis. Traditional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, have limited efficacy in advanced liver cancer. Thus, novel and effective treatment modalities are urgently needed to improve the situation. Gene therapy, which involves the transfer of a therapeutic gene to diseased cells or tissues using a vector (viral or non-viral), represents a novel promising therapeutic method.
Major risk factors associated with HCC include:
- Chronic hepatitis B virus (HBV) infection
- Chronic hepatitis C virus (HCV) infection
- Alcohol-related liver disease
- Non-alcoholic fatty liver disease (NAFLD) and NASH
- Cirrhosis and chronic liver inflammation
Figure 1. Overview of key risk factors associated with hepatocellular carcinoma (HCC).1
HCC development is typically characterized by complex molecular alterations, including dysregulation of oncogenic signaling pathways, genomic instability, and aberrant cellular proliferation. Due to these factors, the disease often progresses silently during early stages and is frequently diagnosed only after reaching advanced stages.
Limitations of Current Therapies
Despite significant advancements in clinical oncology, the therapeutic landscape for HCC remains fraught with profound challenges. Current treatment strategies are highly dependent on the stage of the disease at the time of diagnosis:
- Surgical Resection & Liver Transplantation: These remain the only potentially curative options. However, they are strictly reserved for early-stage patients who meet stringent criteria.
- Targeted Therapy: Systemic treatments using multikinase inhibitors like Sorafenib and Lenvatinib have been the standard of care for advanced HCC. While they inhibit tumor angiogenesis and proliferation, they only offer a modest extension of overall survival
Targeting Strategies
| Target | Relevance |
|---|---|
| GPC3 | Highly expressed in HCC tumors |
| AFP | Classic liver cancer biomarker |
| ASGPR | Hepatocyte-specific receptor |
| VEGFR | Angiogenesis signaling |
Adenovirus Gene Therapy for HCC
Adenovirus has been the most common gene transfer vector for cancer gene therapy in the past decades due to a number of unique advantages that make them attractive in gene therapy, including (i) the ability to infect a broad range of cell types with high efficiency and achieve high levels of transgene expression, (ii) capability of transducing both replicating and non-replicating cells, (iii) easy acquisition of high titers, and (iv) stable genome where foreign genes can be inserted and maintained without change through successive rounds of viral replication.
Because traditional adenovirus lacks the ability to target liver cancer, various strategies have been developed to achieve tumor-specific targeting. Firstly, one strategy is to use cancer or tissue-specific promoter to control the expression of the viral essential gene for replication, which is called the transcriptionally targeted strategy. In this way, the virus could only replicate in tumor cells and kill them. Secondly, the tumor signaling pathway can be targeted by deletion or mutation of key adenovirus genes or some bases that are necessary for adenovirus replication in normal cells but not in tumor cells, such as the E1B 55 kDa gene. Thirdly, as adenovirus efficiently infect host cells by binding to specific receptors via fibers on the capsid, modification of the adenovirus capsid may improve the ability of adenovirus to bind target cells. For instance, antibody-modified or peptide-incorporated adenoviral vectors can be constructed to achieve retargeting.
Strategic Importance of Adenovirus Vectors in HCC Gene Therapy
Adenovirus vectors possess several unique biological features that make them highly suitable for cancer gene therapy applications. Key advantages include:
- High Gene Delivery Efficiency
Adenoviruses can infect a wide variety of cell types, including both dividing and non-dividing cells. This broad tropism enables efficient gene delivery into tumor tissues.
- Large Packaging Capacity
Adenoviral vectors can accommodate relatively large transgene inserts, typically up to 7–8 kb, enabling delivery of complex therapeutic genes or multi-gene constructs.
- Strong Transgene Expression
Because adenovirus vectors remain episomal within host cells, they can produce robust transgene expression, which is critical for achieving therapeutic effects in cancer treatment.
- Non-Integrating Genome
Unlike lentiviral vectors, adenovirus vectors do not integrate into the host genome, reducing the risk of insertional mutagenesis.
Key Challenges in Developing HCC-Targeting Adenoviral Vectors
Despite their advantages, developing effective tumor-targeting adenoviral vectors presents several technical challenges.
| Challenge | Description |
|---|---|
| Tumor specificity | Achieving selective infection of HCC cells without affecting normal hepatocytes |
| Immune response | Rapid immune clearance of adenovirus particles |
| Receptor expression variability | Some tumor cells express low levels of adenovirus entry receptors |
| Off-target toxicity | Potential damage to normal liver tissue |
| Genetic stability | Maintaining vector stability during amplification |
| Large-scale production | Efficient production of high-titer viral stocks |
Overcoming these challenges requires advanced viral engineering strategies and optimized vector design.
Our HCC-Targeting Adenovirus Vector Construction Services
Creative Biolabs offers a modular, fully customizable suite of services. Whether you need a simple gene-delivery vector or a complex, multi-armed oncolytic virotherapy, we deliver with uncompromising quality.
| Service Module | Description |
|---|---|
| Vector Design | Custom adenovirus backbone design utilizing state-of-the-art bioinformatics. We assist in selecting the optimal serotype, promoters, and structural modifications tailored specifically to your project's goals. |
| Targeting Engineering | Precise Fiber knob modifications, RGD insertion, or custom ligand display on the pIX protein to ensure maximum entry into therapy-resistant HCC cell lines. |
| Promoter Selection | Rigorous screening and integration of tumor-specific promoters to restrict transgene expression or viral replication exclusively to malignant liver cells. |
| Gene Insertion | Seamless Gene of Interest (GOI) cloning into the E1, E3, or E4 regions of the adenovirus genome. We can accommodate single genes, massive multi-gene cassettes, or complex shRNA/miRNA expression systems. |
| Virus Packaging | High-efficiency viral rescue and amplification in specialized HEK293 cell lines. Our optimized transfection and harvest protocols guarantee maximum initial viral yield and prevent premature cell death during production. |
| Virus Purification | We offer flexible purification scales. Depending on your needs, we utilize ultracentrifugation for extreme purity, or scalable column chromatography for massive batch yields. |
| Quality Control | Comprehensive QC testing including precise measurement of physical titer (VP/mL), infectious titer, strict sterility testing, mycoplasma detection, and RCA screening for non-oncolytic vectors. |
| Functional Validation | Robust in vitro transduction assays utilizing your specified HCC cell lines to visually and quantitatively confirm targeting efficiency, transgene expression, and oncolytic cytotoxicity. |
Applications of HCC-Targeting Adenovirus Vectors
The vectors engineered at Creative Biolabs act as a highly versatile foundation for multiple advanced therapeutic modalities against hepatocellular carcinoma.
- Cancer Gene Therapy: Delivering critical tumor suppressor genes that are frequently mutated or deleted in HCC. For instance, restoring functional p53 to trigger apoptosis in resistant tumors, or delivering PTEN to suppress uncontrolled PI3K/AKT proliferation signaling.
- Oncolytic Virotherapy: Utilizing conditionally replicating adenoviruses to induce direct, selective tumor cell lysis. As the tumor cells burst, they release highly infectious viral progeny that sweep through the tumor mass, dismantling it from the inside out while sparing healthy liver tissue.
- Immunotherapy Enhancement: The HCC tumor microenvironment is notoriously "cold" and immunosuppressive. By delivering cytokine-armed adenoviruses, the virus acts as a biological flare, violently altering the microenvironment to become "hot" and actively recruiting cytotoxic T-lymphocytes and Natural Killer cells to the tumor bed.
- Cancer Vaccine Development: Adenoviruses can be highly engineered to deliver highly specific HCC tumor-associated antigens (TAAs) or patient-specific neoantigens to dendritic cells, thereby priming a robust, systemic, and long-lasting anti-tumor adaptive immune response.
- Tumor Microenvironment Modulation: Delivering genes that encode localized immune checkpoint blockade therapies directly into the tumor. This localized expression prevents the severe systemic autoimmune toxicities commonly associated with intravenous monoclonal antibody therapies.
Why Choose Creative Biolabs?
In the highly competitive and technically demanding field of gene therapy, precision and reliability are non-negotiable. Creative Biolabs stands apart as a premier partner for your HCC research:
- Extensive Experience in Viral Vector Engineering: We have successfully constructed thousands of custom viral vectors for top-tier academic institutions and leading pharmaceutical companies worldwide.
- Customized Tumor-Targeting Strategies: We do not believe in off-the-shelf solutions for complex diseases. Every vector is a bespoke creation, meticulously engineered to solve your specific biological hypothesis.
- High-Efficiency Virus Production Platform: Our proprietary upstream and downstream processes guarantee exceptional viral yields and industry-leading purity, saving you critical time and grant funding.
- Comprehensive QC System: We subject every batch to the most rigorous quality control standards in the industry, ensuring uncompromised safety and total reproducibility for your data.
- Global Scientific Support: You are partnered with dedicated, PhD-level virologists who provide continuous, insightful technical consultation from the initial blueprint design to post-delivery experimental troubleshooting.
Customer Reviews
Frequently Asked Questions (FAQ)
Q: What types of genes can be delivered using your adenovirus vectors?
A: Our adenoviral vectors have a large packaging capacity of up to ~8 kb. This generous capacity allows for the delivery of a wide variety of genetic material, including large tumor suppressor genes, complex immunomodulatory cytokines, suicide genes, reporter genes, and even multi-gene cassettes driven by independent promoters. We can also package shRNA or miRNA sequences for potent gene knockdown applications.
Q: Can you design tumor-specific adenoviruses exclusively for liver cancer?
A: Yes, absolutely. Liver cancer is one of our core areas of expertise. We employ dual-targeting strategies specifically designed for HCC. This includes utilizing liver-cancer-specific promoters to control viral replication or transgene expression, alongside sophisticated capsid modifications to ensure the virus binds only to malignant cells, effectively avoiding healthy surrounding hepatocytes.
Q: Do you provide in vitro functional validation services before shipment?
A: Yes. We believe a vector must be proven to work before it leaves our facility. Our comprehensive service includes robust in vitro validation. We utilize your target HCC cell lines to assess transduction efficiency, confirm transgene expression via Western blot or flow cytometry, and validate the tumor-specific cytotoxicity of oncolytic vectors using advanced cell viability assays. You receive this data as part of your final report.
Q: Can your adenovirus vectors be used for oncolytic virotherapy development?
A: Definitely. Oncolytic virotherapy is a major pillar of our viral engineering platform. We can custom-build conditionally replicating adenoviruses by introducing critical mutations into the E1A/E1B regions or by placing vital replication genes under the strict control of tumor-specific promoters. We can further "arm" these oncolytic viruses with immune-stimulating genes to create powerful therapeutic agents that not only lyse the tumor but also trigger a systemic anti-cancer immune response.
Connect with Us Anytime!
At Creative Biolabs, you will find the most comprehensive customized viral and non-viral vector design and construction services at the most competitive prices. We are happy to share our expertise and technologies to promote your project a success. Please contact us for further information about our services and get a quote.
Reference
- Ermi A G, Younis R M, Rodriguez K, et al. Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions. Cancers, 2025, 17(22): 3608. https://doi.org/10.3390/cancers17223608 Distributed under Open Access license CC BY 4.0, without modification.
